Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

NCT06485089 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can be safely and effectively studied in people with obesity who may have an increased risk of breast cancer, by measuring changes in blood, imaging, and breast tissue biomarkers.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 20 people Planned (estimated).

Who can join Ages 40–64 · female only Healthy volunteers accepted.

Timeline Started 2024-09 · est. completion 2026-04

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06485089 ↗

Description as written by the study sponsor.

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Treatments tested

tirzepatide Drug

Women taking tirzepatide as part of standard care in the Weight Managment Clinic

Main thing measured	Feasibility of design as assessed by accrual rate of 1 or more per month over 12 months
Sponsor	University of Kansas Medical Center
Conditions studied	Obesity, Breast Cancer Risk
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06485089 ↗